AORT Stock Overview
Artivion, Inc. manufactures, processes, and distributes medical devices and implantable human tissues worldwide.
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Artivion, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$15.49 |
| 52 Week High | US$23.43 |
| 52 Week Low | US$9.64 |
| Beta | 1.39 |
| 1 Month Change | 5.37% |
| 3 Month Change | 31.94% |
| 1 Year Change | -11.64% |
| 3 Year Change | -29.43% |
| 5 Year Change | -46.68% |
| Change since IPO | 287.25% |
Recent News & Updates
Artivion's (NYSE:AORT) Returns On Capital Are Heading Higher
May 10
Artivion (NYSE:AORT) Has A Somewhat Strained Balance Sheet
Mar 09Recent updates
Artivion's (NYSE:AORT) Returns On Capital Are Heading Higher
May 10Artivion (NYSE:AORT) Has A Somewhat Strained Balance Sheet
Mar 09Artivion Non-GAAP EPS of $0.10 beats by $0.12, revenue of $79.4M misses by $0.77M
Feb 16Artivion: PROACT Xa Overhang Remains Well In Situ, Reaffirm Hold
Dec 18Artivion (NYSE:AORT) Is Making Moderate Use Of Debt
Sep 29Artivion: Stopping PROACT Xa Trial Removes Long-Term Growth Driver
Sep 27Artivion Non-GAAP EPS of -$0.03 misses by $0.06, revenue of $80.34M beats by $3.07M
Aug 04Is Artivion (NYSE:AORT) Using Too Much Debt?
Jun 27Is Artivion (NYSE:AORT) Using Too Much Debt?
Mar 25CryoLife (NYSE:CRY) Has A Somewhat Strained Balance Sheet
Dec 08CryoLife, Inc. (NYSE:CRY) Second-Quarter Results: Here's What Analysts Are Forecasting For This Year
Aug 01CryoLife (NYSE:CRY) Takes On Some Risk With Its Use Of Debt
Jul 30Cryolife (CRY) Investor Presentation - Slideshow
May 28CryoLife (NYSE:CRY) Seems To Be Using A Lot Of Debt
Feb 05CryoLife: Upside Potential Via Operating Leverage But Liquidity Pressures Loom
Dec 16Shareholder Returns
| AORT | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | 4.9% | 0.9% | 2.6% |
| 1Y | -11.6% | 3.3% | 2.1% |
Return vs Industry: AORT underperformed the US Medical Equipment industry which returned 3.3% over the past year.
Return vs Market: AORT underperformed the US Market which returned 2.1% over the past year.
Price Volatility
| AORT volatility | |
|---|---|
| AORT Average Weekly Movement | 6.1% |
| Medical Equipment Industry Average Movement | 7.7% |
| Market Average Movement | 6.7% |
| 10% most volatile stocks in US Market | 15.9% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: AORT is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 6% a week.
Volatility Over Time: AORT's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1984 | 1,300 | Pat Mackin | https://artivion.com |
Artivion, Inc. manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company offers BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and E-vita Open Plus and E-vita Open Neo. It also provides E-xtra design engineering systems for the treatment of aortic vascular diseases; E-nside, an off-the-shelf stent graft for the treatment of thoraco-abdominal disease; E-vita THORACIC 3G for the endovascular treatment of thoracic aortic aneurysms; E-nya, a thoracic stent and graft system for the minimally invasive repair of lesions of the descending aorta; E-ventus BX, a balloon-expandable peripheral stent graft for the endovascular treatment of renal and pelvic arteries; E-liac to treat aneurysmal iliac arteries, and aneurysmal iliac side branches; and E-tegra, an abdominal aortic aneurysms stent graft system.
Artivion, Inc. Fundamentals Summary
| AORT fundamental statistics | |
|---|---|
| Market Cap | US$633.16m |
| Earnings (TTM) | -US$29.19m |
| Revenue (TTM) | US$319.81m |
2.0x
P/S Ratio-21.7x
P/E RatioIs AORT overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| AORT income statement (TTM) | |
|---|---|
| Revenue | US$319.81m |
| Cost of Revenue | US$114.27m |
| Gross Profit | US$205.53m |
| Other Expenses | US$234.73m |
| Earnings | -US$29.19m |
Last Reported Earnings
Mar 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.71 |
| Gross Margin | 64.27% |
| Net Profit Margin | -9.13% |
| Debt/Equity Ratio | 110.0% |
How did AORT perform over the long term?
See historical performance and comparison